Clifford Capital Partners LLC Purchases 138,203 Shares of Kenvue Inc. (NYSE:KVUE)

Clifford Capital Partners LLC increased its holdings in Kenvue Inc. (NYSE:KVUE) by 21.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 788,451 shares of the company’s stock after acquiring an additional 138,203 shares during the quarter. Kenvue makes up about 3.1% of Clifford Capital Partners LLC’s investment portfolio, making the stock its 17th largest position. Clifford Capital Partners LLC’s holdings in Kenvue were worth $14,334,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Manchester Capital Management LLC boosted its position in Kenvue by 80.8% during the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares in the last quarter. Mather Group LLC. purchased a new stake in shares of Kenvue during the first quarter valued at about $28,000. Riverview Trust Co bought a new stake in shares of Kenvue in the 1st quarter valued at about $33,000. MV Capital Management Inc. grew its position in shares of Kenvue by 71.2% in the 1st quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after buying an additional 642 shares during the last quarter. Finally, Salomon & Ludwin LLC bought a new position in shares of Kenvue during the 1st quarter worth approximately $33,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Down 1.5 %

KVUE stock opened at $22.79 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. The firm’s fifty day simple moving average is $21.60 and its 200-day simple moving average is $20.11. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $23.55. The company has a market capitalization of $43.63 billion, a P/E ratio of 29.21, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.28 by $0.04. The company had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The firm’s revenue was down .3% on a year-over-year basis. During the same period in the prior year, the company earned $0.32 earnings per share. As a group, equities research analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current year.

Kenvue Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Shareholders of record on Wednesday, August 14th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, August 14th. This is an increase from Kenvue’s previous quarterly dividend of $0.20. This represents a $0.82 dividend on an annualized basis and a yield of 3.60%. Kenvue’s payout ratio is presently 105.13%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on KVUE shares. Citigroup cut their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research note on Tuesday, September 24th. JPMorgan Chase & Co. upped their price objective on shares of Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Jefferies Financial Group started coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price for the company. Finally, Piper Sandler upped their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research note on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average price target of $22.10.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.